Sonata Therapeutics lures former Kite exec to be its CSO

21 March 2023

US biotech Sonata Therapeutics today announced the appointment of Dr Francesco Marincola as its chief scientific officer (CSO).

Sonata, which is creating therapeutics that transform diseased cells into coordinators of cure, was launched last year by USA-based biotech incubator Flagship Pioneering, and was formed by combining two Flagship companies, Inzen Therapeutics and Cygnal Therapeutics.

At Sonata, Dr Marincola will be responsible for accelerating the company’s vision to deliver novel therapeutics that reprogram diseased cells to drive robust, durable, and comprehensive cures for a broad range of diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK